PDCD1 and cancer: Recent studies mainly describe a potential co-administration of gemcitabine and paclitaxel also with other drugs, such as nivolumab, human IgG4 monoclonal antibody which blocks the immune checkpoint—programmed cell death protein 1 (CD-279), which sensitizes cancer cells for the immune system and causes the induction of immunogenic cell death.